EFFICACY OF ORMELOXIFENE IN MANAGEMENT OF DYSFUNCTIONAL UTERINE BLEEDING
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i11.27883Keywords:
Dysfunctional uterine bleeding, Ormeloxifene, Hemoglobin, Menorrhagia, Selective estrogen receptor modulatorsAbstract
Objective: The objective was to evaluate the efficacy of ormeloxifene in dysfunctional uterine bleeding (DUB) with respect to bleeding pattern and improvement in hemoglobin (Hb).
Methods: This was an interventional study on 99 patients of DUB visiting the gynecology outpatient department over 1 year using semi-structured pro forma. After voluntary participation of patients, tablet ormeloxifene was given at the dose of 30 mg biweekly for 2 months. In case of a therapeutic response as informed by the patient, the dose was reduced to 30 mg weekly for a further period of 4 months. All patients were treated for 6 months. Type, amount, and duration of bleeding, frequency of menstrual cycle, passage of clots, and impact on Hb were assessed.
Result and Observations: Menorrhagia was the main type of bleeding. 36–40 years of age group was the most common. After the intervention, 76.8% of women achieved a duration of bleeding of 4–5 days, and in 87% of women, menstrual cycle became regular. Passage of clots was reduced by 71.83%. Mean Hb concentration of study participants increased by 0.5 g/dl at the end of the study.
Conclusion: Ormeloxifene is effective alternative and appears to be a promising option for the medical management of DUB.
Downloads
References
Bellad GC, Lakshmi KS. Ormeloxifene in the management of dub. J Evid Based Med Healthcare 2015;2:6125-31.
Annigeri C, Katti T, Karaddi S. Histopathological spectrum of endometrium in dysfuctional uterine bleeding with respect to age, parity and bleeding pattern. BMR Med 2014;1:1-12.
Butler WJ. Normal and abnormal uterine bleeding. In: Rock AJ, Jones HW, editors. TeLinde’s Operative Gynaecology. 9th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2003. p. 461.
Chen BH, Guidice LC. Dysfunctional uterine bleeding. West J Med 1998;169:280-4.
Awwad JT, Toth TL, Schiff I. Abnormal uterine bleeding in the perimenopause. Int J Fertil 1993;38:261.
Goldstein SR, Nanavati N. Selective oestrogen receptor modulator levormeloxifene in the treatment of osteoporosis. Am J Obstetr Gynaecol 2002;187:521.
Yadav VK. Centchroman: A better alternative for hormonal oral Contraceptive pills. Int J Pharm BioSci 2011;2:587-92.
Lai J. Clinical pharmacokinetics and interaction of centchroman - A mini review. Contraception 2010;81:275-80.
Zaidi D, Singh N, Ahmed IZ, Sharma R, Balapure A. Ant proliferative effects of curcumin plus centchroman in MCF-7 and MDA MB-231 cells. Int J Pharm Pharm Sci 2011;3:2212-16.
Hebbar S. Epilepsy and oral hormonal contraception-Indian perspective. Int J Pharm Pharm Sci 2017;9:1-6.
Mandal D, Parmanik S, Surana S, Hazra A, Mandal S, Maity TK. Comparative study of low-dose oral contraceptive pill and ormeloxifene in the treatment of dysfunctional uterine bleeding. Int J Health Allied Sci 2014;3:225-31.
Shabab F, Jain S, Jain J, Jain U. Ormeloxifene: Boon to perimenopausal dysfunctional uterine bleeding (DUB) women in avoiding hysterectomies. Int J Med Sci Educ 2014;1:21-9.
Agarwal N, Singh S. the efficacy and safety of ormeloxifene in dysfunctional uterine bleeding. J Pharm Biol Sci 2013;5:18-21.
Grover S, Chhabra A, Bindu S. a study of ormeloxifene in case of dysfunctional uterine bleeding. Int J Med and Dent Sci 2013;2:162-9.
Komaram R, Palla J, Chintada GS. A study of efficacy of ormeloxifene in the pharmacological management of dysfunctional uterine bleeding. J Clin Diag Res 2013;7:2534-6.
Godha Z, MOhsin Z, Hakim S, Waseem S. Comparative study of ormeloxifene and medroxyprogesterone acetate in abnormal uterine bleeding. J Obstetr Gynecol India 2016;66:S395-9.
Soniya P, Verma A, Verma P, Gupta R, Sharma B. Role of ormeloxifene in management of abnormal uterine bleeding. Sch J App Med Sci 2017;5:796-9.
Singh HO, Singh A, Dhole TN, Nain S. Effect of ormeloxifene for management of dysfunctional uterine bleeding. Biochem Physiol 2015;4:174.
Bhattacharyya TK, Banerji A. Efficacy of selective estrogen receptor modulator: Ormeloxifene in management of dysfunctional uterine bleeding. South Asian Fed Obstetr Gynecol 2010;2:207-11.
Jacob KJ, Mini, Deepak AV. A comparative study on the effectiveness of ormeloxifene versus norethisterone in the management of perimenopausal dysfunctional uterine bleeding. IAIM 2015;2:87-92.
Ahmed SB, Mogri S, Barala S. Role of ormeloxifene in the management of dysfunctional uterine bleeding: A prospective study. Int J Reprod Contracept Obstet Gynecol 2016;5:4373-6.
Dhananjay BS, Nanda SK. Role of sevista in the management of dysfunctional uterine bleeding. J Clin Diag Res 2013;7:132-4.
Khan SA, Manzoor M, Abdullah A, Banoo A. Efficacy and safety of ormeloxifene in the management of dysfunction uterine bleeding. J Dent Med Sci 2014;13:39-42.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
